AbbVie's Temab-A Wins Two FDA Breakthrough Tags

FDA granted AbbVie two separate Breakthrough Therapy Designations on 7 October 2026 for the same antibody-drug conjugate, telisotuzumab adizutecan (Temab-A, ABBV-400) — one pairing it with bevacizumab in refractory metastatic colorectal cancer, the other for Temab-A alone in a biomarker-defined population of non-small cell lung cancer that had already progressed on chemotherapy and immunotherapy. Both are the first Breakthrough designations Temab-A has received.

One target, two tumor types, two designations

c-Met (MET) is overexpressed across a range of solid tumors, and AbbVie is testing Temab-A against it on two separate fronts at once rather than waiting to sequence one indication before starting the next. The colorectal designation covers Temab-A combined with bevacizumab in patients whose disease has already progressed through the standard late-line sequence — fluoropyrimidine, irinotecan, oxaliplatin and an anti-VEGF agent. The lung designation is narrower on biomarker grounds: it is limited to non-squamous NSCLC that is EGFR wild-type (not EGFR-mutant) and c-Met-expressing, in patients who have already failed platinum-based chemotherapy and an anti-PD-(L)1 checkpoint inhibitor. AbbVie's Eleni Lagkadinou, vice president of oncology early development, said the pair of designations reflects growing clinical evidence that c-Met is a meaningful target across more than one solid-tumor type, not just one.

What the public data shows, and doesn't

AbbVie attributes both designations primarily to first-in-human Phase 1 study M21-404 (NCT05029882). The clearest public dataset that lines up with the colorectal designation is a randomized dose-optimization cohort of Temab-A plus bevacizumab, presented at ASCO in an unselected metastatic colorectal cancer population: an objective response rate of 30% and a median progression-free survival of 6.8 months at the recommended Phase 2 dose, in 30 patients. That is a single mid-sized cohort, not a registration-size trial, and AbbVie's announcement of the designations did not publish response data specific to the EGFR-wild-type NSCLC subgroup the second designation actually covers — a different, narrower population than the EGFR-mutant NSCLC cohort AbbVie has presented data on separately. Readers should not assume the two datasets are interchangeable; they are not the same trial arm.

What it means for RA/QA teams

Breakthrough Therapy Designation buys a sponsor more frequent FDA interaction, eligibility for rolling review, and senior-manager engagement — it does not lower the evidentiary bar for an eventual approval, and it is not itself an approval signal. For teams tracking the c-Met ADC class, the more useful fact here is procedural: FDA evaluated and granted two designations for the same molecule on the same day, scoped to two distinct combination/monotherapy and biomarker populations rather than one blended label strategy. That is a template other sponsors developing multi-indication ADCs are likely to follow, and it is a reminder that a single designation announcement can cover materially different patient populations that deserve separate scrutiny of the underlying data, not one combined read.

Frequently asked questions

What did FDA grant AbbVie on 7 October 2026?

Two separate Breakthrough Therapy Designations for telisotuzumab adizutecan (Temab-A, ABBV-400): one for Temab-A plus bevacizumab in refractory metastatic colorectal cancer, and one for Temab-A alone in previously treated, EGFR-wild-type, c-Met-expressing non-squamous NSCLC.

What clinical data supports the designations?

AbbVie cites first-in-human Phase 1 study M21-404 (NCT05029882). A related randomized dose-optimization cohort of Temab-A plus bevacizumab in mCRC reported a 30% ORR and 6.8-month median PFS at the recommended Phase 2 dose (n=30); AbbVie did not publish response data specific to the EGFR-wild-type NSCLC subgroup.

What does Breakthrough Therapy Designation actually change?

More frequent FDA interaction, rolling-review eligibility and intensive development guidance. It is a development-acceleration status, not evidence the drug works or that approval is near.

Why two designations for one drug in one day?

The two indications rest on different combination partners, biomarker populations and prior-therapy requirements, so FDA evaluated them separately. AbbVie says the pairing reflects growing evidence for c-Met as a target across more than one tumor type.